ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / TLX / earnings
DYN (28) IDYA (35) ELVN (41) BHC (69) ⌘ Pro Terminal →

Telix Pharmaceuticals Limited (TLX) Next Earnings Date & Expected ±4.1% Move

$9.10 -4.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.01

Telix Pharmaceuticals Limited (TLX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $3.22B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Telix Pharmaceuticals Limited (NASDAQ: TLX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.10 (-4.31% 1D, market cap $3.22B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TLX ranks #336 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TLX compare to DYN and IDYA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DYN (Dyne Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $3.18B) and IDYA (IDEAYA Biosciences Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -13.8%, cap $3.17B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TLX?
▼

For Telix Pharmaceuticals Limited (TLX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #336 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.01 (-0.97%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 2.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
$14 Bull$9 Base$7 Bear
📬 FREE TLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLX)Realized 20D OHLCV Swing Band: ±4.1%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY TLX SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 2.3% FCF Margin ($90.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$11.29-4.9% Next Q
Q2 (-2Q)
52
Grade C-$10.74-16.3% Next Q
Q3 (-1Q)
50
Grade C-$8.99+1.2% Next Q
Current
47
Grade D$9.10-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TLX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TLX currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.02) and Max Pain ($9.56) forces dealer call-delta covering toward $13.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TLX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±4.1% Swing Band

±$0.37 Expected Swing
$8.73 (-4.1%)Spot $9.10$9.47 (+4.1%)
MODEL EARNINGS SETUP GAUGE

TLX Quantitative Pre-Earnings Setup: 47/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (47/100)Model Risk Weight (53/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLX)

  • ✓Walkthrough of TLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.39%🛡️ HOLDING TREND SUPPORT
2026-11-02O $9.26H $9.51L $9.10C $9.10VOL 211.3K
RES: $13.71SUP: $8.85SMA50: $11.02SMA200: $9.92
$13.42$12.14$10.86$9.57$8.29RES $13.71SUP $8.85$9.102026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TLX Butterfly Map → + Track TLX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLX)

Health Care Rank #336 of 1016 ⚔️ DYN vs TLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TLX vs. DYN, IDYA, ELVN, BHC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Telix Pharmaceuticals Limited (TLX) ranks #336 by composite RQD confidence (47/100, grade D) and #201 by equity capitalization ($3.22B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with TLX at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TLX ACTIVE
Telix Pharmaceuticals Limited
D 47/100 — — — -4.31% $3.22B Benchmark Subject
DYN
Dyne Therapeutics Inc.
E 28/100 — — -35.0% -2.05% $3.18B /dyn-vs-tlx →
IDYA
IDEAYA Biosciences Inc.
D- 35/100 — — -13.8% -2.83% $3.17B /idya-vs-tlx →
ELVN
Enliven Therapeutics Inc.
D- 41/100 — — -26.2% -1.84% $3.30B /elvn-vs-tlx →
BHC
Bausch Health Companies Inc.
C+ 69/100 21.2x — 7.6% -7.97% $3.33B /bhc-vs-tlx →

2. TLX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Telix Pharmaceuticals Limited (TLX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $3.22B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. TLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Telix Pharmaceuticals Limited (NASDAQ: TLX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.10 (-4.31% 1D, market cap $3.22B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TLX ranks #336 in composite RQD confidence.

How does TLX compare to DYN and IDYA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DYN (Dyne Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $3.18B) and IDYA (IDEAYA Biosciences Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -13.8%, cap $3.17B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TLX?

For Telix Pharmaceuticals Limited (TLX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #336 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TLX trading relative to its 50-day, 200-day, and 52-week technical levels?

TLX last traded at $9.10 (-4.31% on volume of 341,900 shares), positioning the stock -17.42% below its 50-day simple moving average ($11.02) and -8.27% below its 200-day simple moving average ($9.92). Across its 52-week range of $6.28 to $13.11, TLX sits at the 41.3% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±4.1% ($8.73 to $9.47).

TLX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is TLX's next earnings date?

Based on SEC filing cadence, Telix Pharmaceuticals Limited (TLX)'s next quarterly reporting window is estimated around Upcoming Quarter.

How much is TLX stock expected to move on earnings?

Volatility modeling currently projects a ±4.1% event move for TLX, spanning a range between $8.73 and $9.47.

Direct Sub-Reports: TLX RQD Cockpit TLX 12M Forecast TLX Earnings & Move TLX Dividends & DRIP TLX Insiders & 13F TLX Whale Options TLX Profit Sankey TLX News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TLX — Telix Pharmaceuticals Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:11:58Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TLX scores 47 out of 100, earning a letter grade of D and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12 / 20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 5 / 20 (institutional accumulation and options positioning), Insider Conviction at 9 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillars are Whale 13F Flow and Macro Regime Fit, which together signal limited institutional conviction and sector-level sensitivity. The cash-engine pillar reflects a reported 0% ROIC and 0% FCF yield, meaning the rating does not credit the company with current cash-generation returns. The balance-sheet pillar is the strongest, supported by a Piotroski F of 6/9 and a Debt/Equity of 0.5. For a prospective investor, the rating implies that upside drivers are not currently evidenced in the cash-return metrics, and that any thesis would rest on forward catalysts rather than present earnings power. Valuation tradeoffs cannot be fully assessed because P/E, Forward P/E, and EV/EBITDA are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items reference TLX:

  • Market-wire coverage (YELLOW): Yahoo! Finance Canada and Yahoo Finance Australia reports cover market action and positioning, with no specific operational detail in the summaries.
  • Seeking Alpha (YELLOW): Headline states "Merger Bodes Well For Long-Term Plan," indicating a merger is referenced; deal terms are not in source data.
  • TradingView (RED, RISK WATCH): Headline reports a 12-month price target cut to $17.95, which the headline states implies 61% upside. This is the only item flagged RED.
  • Marketscreener (YELLOW): Headline references unaudited revenue results for the quarter ended September 30, 2026; figures are not in source data.
  • MarketBeat (YELLOW): Headline reports shares gapped down; magnitude is not in source data.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.

Open Questions

  • What are the terms and status of the merger referenced in the Seeking Alpha item, and how would it affect the long-term plan?
  • What were the unaudited revenue results for the quarter ended September 30, 2026, and how do they compare to prior periods?
  • What drove the price-target reduction flagged RED, and what is the basis for the implied 61% upside cited in that headline?
  • What products, customers, and revenue sources generate the company's income, given that margins and ROIC are reported at 0%?
  • What is the underlying basis for the forensic scores (Altman Z 2.5, Piotroski F 6/9), and what do the full financial statements show?

TLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Telix Pharmaceuticals Limited (TLX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TLX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TLX Bull vs. Bear Conversation Board — What's Your Call at $9.10?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TLX 🐻 50% BEARISH CONVICTION
1. Pick Your Side on TLX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $10.27 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TLX (D • RQD 47/100) a Buy at $9.51?

Welcome to the TLX (Telix Pharmaceuticals Limited) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.89 (-17.0%)
Spot @ $9.51

Pump the brakes on TLX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TLX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Telix Pharmaceuticals Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.94 (+15.0%)
Spot @ $9.51

TLX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TLX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $9.51 (52-wk range $6.28 - $13.11), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%